Ultragenyx Pharmaceutical Inc. and Ligand Pharmaceuticals Incorporated: SG&A Spending Patterns Compared

Ultragenyx vs. Ligand: A Decade of SG&A Spending

__timestampLigand Pharmaceuticals IncorporatedUltragenyx Pharmaceutical Inc.
Wednesday, January 1, 20142257000010811000
Thursday, January 1, 20152437800033001000
Friday, January 1, 20162662100064936000
Sunday, January 1, 20172865300099909000
Monday, January 1, 201837734000127724000
Tuesday, January 1, 201941884000161524000
Wednesday, January 1, 202064435000182933000
Friday, January 1, 202157483000219982000
Saturday, January 1, 202270062000278139000
Sunday, January 1, 202352790000309799000
Loading chart...

In pursuit of knowledge

SG&A Spending Patterns: Ultragenyx vs. Ligand

In the competitive landscape of pharmaceuticals, understanding spending patterns is crucial. Over the past decade, Ultragenyx Pharmaceutical Inc. and Ligand Pharmaceuticals Incorporated have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Ultragenyx's SG&A expenses surged by approximately 2,765%, reflecting its aggressive growth strategy. In contrast, Ligand's expenses increased by about 134%, indicating a more conservative approach.

A Decade of Change

Ultragenyx's spending peaked in 2023, with expenses reaching nearly 310 million, a stark contrast to its modest 10.8 million in 2014. Ligand, while more stable, saw its highest expenditure in 2022, with a 210% increase from 2014. This divergence highlights differing strategic priorities: Ultragenyx's focus on rapid expansion versus Ligand's steady, controlled growth. As the pharmaceutical industry evolves, these spending patterns offer insights into each company's operational focus and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025